Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Xtandi (enzalutamide by Quarter
Xtandi (enzalutamide — alliance & royalty revenue with Astellas) — Worldwide reported YoY (%) (%)
Pfizer Xtandi (enzalutamide: -6.0% in Q2 2026, down 20.0 pts from a year earlier. That is the lowest of the 34 quarters on record here.
Where the Q2 2026 figure comes from
“|| Xtandi (d) | 534 | 566 | (6%) | (6%) | 534 | 566 | (6%) | — | — | — | —”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Xtandi (enzalutamide (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/xtandi-yoy-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.